Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Regeneron (REGN) Pharmaceuticals announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically significant ...

Libtayo exceeded $1 billion in sales for 2024. Regeneron announced positive results from the late-stage C-POST study, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo led to ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Fianlimab (LAG3) for melanoma: Combining fianlimab and Libtayo ... information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted ...

The upcoming report from Regeneron (REGN) is expected to reveal ... The combined assessment of analysts suggests that 'Revenues- Libtayo- Total' will likely reach $338.92 million.